个人中心 - 老虎社区

Raywjj92

IP属地：未知

帖子 · 6帖子 · 6
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- Raywjj92Raywjj92
  ·2021-05-02
  Time to play the game
  3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term Winners
  David Gardner, a co-founder of The Motley Fool, often says that "winners win." And he's exactly righ
  3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term Winners
  1,240 评论
  2
  分享
  举报
- Raywjj92Raywjj92
  ·2021-05-02
  Nice detailed article
  非常抱歉，此主贴已删除
  1,625 评论
  1
  分享
  举报
- Raywjj92Raywjj92
  ·2021-05-01
  Good opportunity?
  非常抱歉，此主贴已删除
  1,398 2
  3
  分享
  举报
- Raywjj92Raywjj92
  ·2021-05-01
  $Qualcomm(QCOM)$Come on Qualcomm
  1,386 评论
  1
  分享
  举报
- Raywjj92Raywjj92
  ·2021-04-28
  Nice article
  5 Ultra-Popular Growth Stocks With 28% to 56% Upside, According to Wall Street
  For 13 months, Wall Street has proved virtually unstoppable. Since hitting a bear market bottom on M
  5 Ultra-Popular Growth Stocks With 28% to 56% Upside, According to Wall Street
  966 评论
  点赞
  分享
  举报
- Raywjj92Raywjj92
  ·2021-02-12
  Great article
  非常抱歉，此主贴已删除
  1,312 评论
  点赞
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3575030447100890","uuid":"3575030447100890","gmtCreate":1611936560419,"gmtModify":1619620831004,"name":"Raywjj92","pinyin":"raywjj92","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/57550c84d835f65dcf57fd3bf7c5d66b","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":16,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":6,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.16","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.07","exceedPercentage":"60.02%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":101497940,"gmtCreate":1619928874980,"gmtModify":1631885488646,"author":{"id":"3575030447100890","authorId":"3575030447100890","name":"Raywjj92","avatar":"https://static.tigerbbs.com/57550c84d835f65dcf57fd3bf7c5d66b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575030447100890","authorIdStr":"3575030447100890"},"themes":[],"htmlText":"Time to play the game&nbsp;","listText":"Time to play the game&nbsp;","text":"Time to play the game","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/101497940","repostId":"1115363330","repostType":4,"repost":{"id":"1115363330","kind":"news","pubTimestamp":1619791216,"share":"https://www.laohu8.com/m/news/1115363330?lang=&edition=full","pubTime":"2021-04-30 22:00","market":"us","language":"en","title":"3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term Winners","url":"https://stock-news.laohu8.com/highlight/detail?id=1115363330","media":"Motley Fool","summary":"David Gardner, a co-founder of The Motley Fool, often says that \"winners win.\" And he's exactly righ","content":"<p>David Gardner, a co-founder of The Motley Fool, often says that \"winners win.\" And he's exactly right. However, he would be the first to tell you that winners don't win<i>all</i>of the time. They have their ups and downs.</p>\n<p>Case in point: Cathie Wood certainly qualifies as a winner. Her ARK Invest exchange-traded funds have ranked among the best-performing ETFs in recent years. Not every stock in those funds has delivered a great return so far in 2021, though.</p>\n<p>Several of the ARK Invest CEO's favorites are actually down year to date. Don't count all of those recent underperformers out just yet, though. These three are among Wood's biggest losers of 2021, and all should still be huge winners over the long run.</p>\n<p>Teladoc Health</p>\n<p><b>Teladoc Health</b>(NYSE:TDOC)shares have fallen more than 15% year to date, and that's weighing on several of Wood's ETFs. Teladoc is the top holding in the<b>ARK Genomic Revolution ETF</b>, the second-largest position in the<b>ARK Innovation ETF</b>, and the fifth-largest holding in the<b>ARK Next Generation Internet ETF</b>.</p>\n<p>It appears that many investors are focusing only on the negatives for Teladoc. For example,in its Q1 update, the company reported a huge net loss and said that U.S. paid membership in the quarter slipped to 51.5 million from 51.8 million in the fourth quarter of 2020.</p>\n<p>However, that's only part of the story. Teladoc's total visits and utilization rate continue to climb. And much of that big loss was related to the company's acquisitions of Livongo and InTouch Health, deals that are already helping drive its revenue growth.</p>\n<p>My view is that Teladoc's downturn will be temporary. The long-term opportunities for the company in virtual care remain exceptionally strong.</p>\n<p>Unity Software</p>\n<p><b>Unity Software</b>(NYSE:U)has been an especially poor performer for Wood this year -- the stock has plunged more than 30%. The gaming platform leader ranks No. 10 among the ARK Next Generation Internet ETF's holdings and No. 12 for the ARK Innovation ETF.</p>\n<p>The main knock against Unity is its slowing growth rate. In the fourth quarter of 2020, the company reported a 39% year-over-year revenue increase. However, that was weaker than its full-year revenue growth rate of 43%. Even more concerning, Unity provided a full-year revenue guidance range for 2021 anticipating growth of 24% at the midpoint.</p>\n<p>I don't think investors should be worried, though. For one thing, the pandemic boosted Unity's growth in 2020. It's not surprising that growth would slow somewhat after such an exceptional year. The company also anticipates taking a one-time hit to revenue in 2021 as advertisers adjust to<b>Apple</b>'s new IDFA user identification method.</p>\n<p>Unity still expects to generate annual revenue growth of at least 30% over the long term. Wood clearly remains a fan of the stock -- her ARK Innovation ETFscooped up more sharesrecently. I think that her optimism in this case is spot on.</p>\n<p>Vertex Pharmaceuticals</p>\n<p><b>Vertex Pharmaceuticals</b>(NASDAQ:VRTX)hasn't been quite as big of a problem for Wood in 2021 as Teladoc and Unity. However, thebiotech stockhas fallen more than 10% year to date. It's the seventh-largest position for the ARK Genomic Revolution ETF.</p>\n<p>Wall Street analysts weren't happy with the Q4 results Vertex reported in February. Although the company narrowly beat revenue expectations, its adjusted earnings came in below analysts' estimates. Vertex also provided guidance for 2021 that anticipated slowing growth.</p>\n<p>However, Vertex still has a big market opportunity ahead for its newest cystic fibrosis treatment, Trikafta/Kaftrio, in Europe. The triple-drug combination quickly became a blockbuster in the U.S. after winning approval. However, its growth curve in Europe will take more time because Vertex has to negotiate reimbursement deals with the healthcare regulators in each individual country.</p>\n<p>I fully expect Vertex will achieve tremendous success outside of the cystic fibrosis market over the next few years. The big biotech seems really confident about the prospects for its candidate gene-editing therapy CTX001 in treating a pair of rare blood disorders: sickle cell disease and beta-thalassemia. It also has other promising pipeline candidates as well as a hefty cash stockpile. Vertex, like Teladoc and Unity, looks like a long-term winner despite its losing ways of late.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term Winners</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term Winners\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-30 22:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/30/3-of-cathie-woods-biggest-losers-of-2021-that-shou/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>David Gardner, a co-founder of The Motley Fool, often says that \"winners win.\" And he's exactly right. However, he would be the first to tell you that winners don't winallof the time. They have their ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/30/3-of-cathie-woods-biggest-losers-of-2021-that-shou/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/04/30/3-of-cathie-woods-biggest-losers-of-2021-that-shou/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115363330","content_text":"David Gardner, a co-founder of The Motley Fool, often says that \"winners win.\" And he's exactly right. However, he would be the first to tell you that winners don't winallof the time. They have their ups and downs.\nCase in point: Cathie Wood certainly qualifies as a winner. Her ARK Invest exchange-traded funds have ranked among the best-performing ETFs in recent years. Not every stock in those funds has delivered a great return so far in 2021, though.\nSeveral of the ARK Invest CEO's favorites are actually down year to date. Don't count all of those recent underperformers out just yet, though. These three are among Wood's biggest losers of 2021, and all should still be huge winners over the long run.\nTeladoc Health\nTeladoc Health(NYSE:TDOC)shares have fallen more than 15% year to date, and that's weighing on several of Wood's ETFs. Teladoc is the top holding in theARK Genomic Revolution ETF, the second-largest position in theARK Innovation ETF, and the fifth-largest holding in theARK Next Generation Internet ETF.\nIt appears that many investors are focusing only on the negatives for Teladoc. For example,in its Q1 update, the company reported a huge net loss and said that U.S. paid membership in the quarter slipped to 51.5 million from 51.8 million in the fourth quarter of 2020.\nHowever, that's only part of the story. Teladoc's total visits and utilization rate continue to climb. And much of that big loss was related to the company's acquisitions of Livongo and InTouch Health, deals that are already helping drive its revenue growth.\nMy view is that Teladoc's downturn will be temporary. The long-term opportunities for the company in virtual care remain exceptionally strong.\nUnity Software\nUnity Software(NYSE:U)has been an especially poor performer for Wood this year -- the stock has plunged more than 30%. The gaming platform leader ranks No. 10 among the ARK Next Generation Internet ETF's holdings and No. 12 for the ARK Innovation ETF.\nThe main knock against Unity is its slowing growth rate. In the fourth quarter of 2020, the company reported a 39% year-over-year revenue increase. However, that was weaker than its full-year revenue growth rate of 43%. Even more concerning, Unity provided a full-year revenue guidance range for 2021 anticipating growth of 24% at the midpoint.\nI don't think investors should be worried, though. For one thing, the pandemic boosted Unity's growth in 2020. It's not surprising that growth would slow somewhat after such an exceptional year. The company also anticipates taking a one-time hit to revenue in 2021 as advertisers adjust toApple's new IDFA user identification method.\nUnity still expects to generate annual revenue growth of at least 30% over the long term. Wood clearly remains a fan of the stock -- her ARK Innovation ETFscooped up more sharesrecently. I think that her optimism in this case is spot on.\nVertex Pharmaceuticals\nVertex Pharmaceuticals(NASDAQ:VRTX)hasn't been quite as big of a problem for Wood in 2021 as Teladoc and Unity. However, thebiotech stockhas fallen more than 10% year to date. It's the seventh-largest position for the ARK Genomic Revolution ETF.\nWall Street analysts weren't happy with the Q4 results Vertex reported in February. Although the company narrowly beat revenue expectations, its adjusted earnings came in below analysts' estimates. Vertex also provided guidance for 2021 that anticipated slowing growth.\nHowever, Vertex still has a big market opportunity ahead for its newest cystic fibrosis treatment, Trikafta/Kaftrio, in Europe. The triple-drug combination quickly became a blockbuster in the U.S. after winning approval. However, its growth curve in Europe will take more time because Vertex has to negotiate reimbursement deals with the healthcare regulators in each individual country.\nI fully expect Vertex will achieve tremendous success outside of the cystic fibrosis market over the next few years. The big biotech seems really confident about the prospects for its candidate gene-editing therapy CTX001 in treating a pair of rare blood disorders: sickle cell disease and beta-thalassemia. It also has other promising pipeline candidates as well as a hefty cash stockpile. Vertex, like Teladoc and Unity, looks like a long-term winner despite its losing ways of late.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":1240,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":101496942,"gmtCreate":1619928614186,"gmtModify":1634209040980,"author":{"id":"3575030447100890","authorId":"3575030447100890","name":"Raywjj92","avatar":"https://static.tigerbbs.com/57550c84d835f65dcf57fd3bf7c5d66b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575030447100890","authorIdStr":"3575030447100890"},"themes":[],"htmlText":"Nice detailed&nbsp;article","listText":"Nice detailed&nbsp;article","text":"Nice detailed article","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/101496942","repostId":"1103106179","repostType":4,"isVote":1,"tweetType":1,"viewCount":1625,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":103773825,"gmtCreate":1619827498567,"gmtModify":1634209707345,"author":{"id":"3575030447100890","authorId":"3575030447100890","name":"Raywjj92","avatar":"https://static.tigerbbs.com/57550c84d835f65dcf57fd3bf7c5d66b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575030447100890","authorIdStr":"3575030447100890"},"themes":[],"htmlText":"Good opportunity?&nbsp;","listText":"Good opportunity?&nbsp;","text":"Good opportunity?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/103773825","repostId":"1165708828","repostType":4,"isVote":1,"tweetType":1,"viewCount":1398,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":103745740,"gmtCreate":1619827235180,"gmtModify":1631884711018,"author":{"id":"3575030447100890","authorId":"3575030447100890","name":"Raywjj92","avatar":"https://static.tigerbbs.com/57550c84d835f65dcf57fd3bf7c5d66b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575030447100890","authorIdStr":"3575030447100890"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/QCOM\">$Qualcomm(QCOM)$</a>Come on Qualcomm","listText":"<a href=\"https://laohu8.com/S/QCOM\">$Qualcomm(QCOM)$</a>Come on Qualcomm","text":"$Qualcomm(QCOM)$Come on Qualcomm","images":[{"img":"https://static.tigerbbs.com/ed08922766e5a885016453299394bd3a","width":"750","height":"1300"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/103745740","isVote":1,"tweetType":1,"viewCount":1386,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":100278931,"gmtCreate":1619619175923,"gmtModify":1634211286629,"author":{"id":"3575030447100890","authorId":"3575030447100890","name":"Raywjj92","avatar":"https://static.tigerbbs.com/57550c84d835f65dcf57fd3bf7c5d66b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575030447100890","authorIdStr":"3575030447100890"},"themes":[],"htmlText":"Nice article","listText":"Nice article","text":"Nice article","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/100278931","repostId":"1138128459","repostType":4,"repost":{"id":"1138128459","kind":"news","pubTimestamp":1619608043,"share":"https://www.laohu8.com/m/news/1138128459?lang=&edition=full","pubTime":"2021-04-28 19:07","market":"us","language":"en","title":"5 Ultra-Popular Growth Stocks With 28% to 56% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1138128459","media":"Motley Fool","summary":"For 13 months, Wall Street has proved virtually unstoppable. Since hitting a bear market bottom on M","content":"<p>For 13 months, Wall Street has proved virtually unstoppable. Since hitting a bear market bottom on March 23, 2020, the broad-based<b>S&amp;P 500</b>has galloped higher by 87%, through this past weekend. This handily outpaces the average bounce-back rally from a bear-market bottom and leaves the historic average annual return for the benchmark index eating dust.</p>\n<p>Yet even at these lofty levels, Wall Street professionals see value. Based on the consensus one-year price targets of Wall Street analysts, five of the most populargrowth stocksoffer implied upside ranging from a low of 28% to as much as 56%.</p>\n<p><img src=\"https://static.tigerbbs.com/d19c9dd5972bb303415e3fb9e20fb2d4\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Shopify: Implied upside of 31%</p>\n<p>First up is my absolute favorite software-as-a-service (SaaS) stock,<b>Shopify</b>(NYSE:SHOP). Even after gaining more than 1,000% over the past 3.5 years, Wall Street believes the company's stock offers an additional 31% upside to $1,434 a share over the next year.</p>\n<p>Shopify's operating model of providing cloud-based e-commerce solutions to (primarily) small businessescouldn't be in a better place at the moment. Although it was initially hit by the pandemic with virtually all other retail-oriented companies, it quickly became apparent that Shopify's e-commerce platform would be a logical beneficiary as businesses shifted course and pushed online. The result was a 96% increase in gross merchandise value (GMV) transacted across its platform in 2020 to $119.6 billion. Over the past six years, GMV has grown at a compound annual rate of 77.7%.</p>\n<p>What's made Shopify tick is both the discovery of the platform by new merchants and the ability to snag worthwhile deals with major retailers. The number of consumers using the platform increased by approximately 52% last year to 457 million. Meanwhile, itpartneredwith the likes of<b>Walmart</b>&nbsp;and<b>Pinterest</b>to streamline aspects of their online sales platforms.</p>\n<p>Shopify isn't remotely inexpensive on a fundamental basis. But if it can continue to grow its GMV at these insane levels, investors will gladly pay a hefty premium to own Shopify stock.</p>\n<p><img src=\"https://static.tigerbbs.com/df219df7b01fbc2aa008c455f28b99e5\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Teladoc Health: Implied upside of 40%</p>\n<p>Telemedicine giant<b>Teladoc Health</b>(NYSE:TDOC)has been exceptionally popular over the past year, for obvious reasons I'll touch on in a moment. According to Wall Street, shares of Teladoc could ascend past $250 over the next 12 months, giving it an implied upside of 40%.</p>\n<p>As you can imagine, physicians wanted to keep at-risk people and potentially infected patients out of offices and hospitals if at all possible last year. This led to Teladoc handling almost 10.6 million virtual visits in 2020, up from around 4.1 million in the previous year.</p>\n<p>But understand that telehealth is agame-changing healthcare modeland not just a one-year wonder because of the pandemic. It's far more convenient for patients, allows physicians to keep closer tabs on at-risk patients, and is usually billed at a lower rate than office visits, which health insurers love. These advantages are exactly why Teladoc's sales grew by an average annual rate of 74% between 2013 and 2019.</p>\n<p>Furthermore, Teladoc has a new toy, so to speak: Itacquired leading applied health signals company Livongo Healthin early November. Livongo leans on artificial intelligence to send tips and nudges to patients with chronic illnesses. These nudges help patients make behavioral changes that result in their leading healthier lives. The addition of Livongo makes Teladoc a veritable no-brainer buy.</p>\n<p><img src=\"https://static.tigerbbs.com/0e47e6b6eced3a10e200ffd777619a0c\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Snowflake: Implied upside of 28%</p>\n<p>Another high-growth stock with abundant upside according to Wall Street professionals is cloud data warehousing company<b>Snowflake</b>(NYSE:SNOW). After recently retracing to an all-time low, analysts see Snowflake gaining up to 28% to almost $301 a share over the next 12 months.</p>\n<p>As I alluded to with Shopify, we're witnessing a big push by businesses online and into the cloud, which has been a boon for most cloud infrastructure companies. Despite the worst economic downturn in decades, Snowflake grew its product revenue by 120% to $553.8 million in fiscal 2021. Although it's losing a lot of money at the moment, the services Snowflake offers should yield juicy margins as the company matures.</p>\n<p>Arguably the most interesting thing about Snowflake is itssustainable competitive advantages. For instance, it offers a pay-as-you-go model that shuns the subscriptions that SaaS stocks often covet. By allowing its customers to pay based on their storage needs and Snowflake Compute Credits used, it's offering a highly transparent and cost-effective operating model.</p>\n<p>Even better, its platform islayered atop the most popular cloud infrastructure solutions, which makes the sharing of information seamless, regardless of storage provider.</p>\n<p>Snowflake has some very big shoes to fill with its lofty valuation, but Wall Street believes the company can get it done.</p>\n<p><img src=\"https://static.tigerbbs.com/bbafad9e87b7b7dacfefe92d4741b655\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Datadog: Implied upside of 35%</p>\n<p>Have I mentioned that Wall Street has a thing forSaaS stocks? In addition to Shopify and Snowflake, analysts believe that application monitoring solutions provider<b>Datadog</b>(NASDAQ:DDOG)could surge to $121 a share over the next year. This implies up to 35% upside in its shares.</p>\n<p>Keeping with the theme, Datadog looks to benefit from businesses completely shifting their strategy in the wake of the pandemic. With employees working remotely, it's become more important than ever that businesses stay on top of key metrics, oversee critical applications, and fully understand the behavior of their customers. Datadog's cloud-based solutions do all of this for its clients.</p>\n<p>What's been most impressive about Datadog is the company's ability to attract bigger clients. While a 46% increase in customers with at least $100,000 in annual recurring revenue (ARR) is nice, the \"wow\" number is the 94% increase in the number of customers generating at least $1 million in ARR. This is a big reason the company's sales shot 66% higher in 2020 to $603.5 million.</p>\n<p>Similar to Snowflake, Datadog has a lot to prove with its lofty price-to-sales ratio. However, if it can continue to grow its sales by more than 30% annually, there'sno reason Wall Street's price target isn't within reach.</p>\n<p><img src=\"https://static.tigerbbs.com/99b3853458b2424e2901821012f5502f\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Coinbase: Implied upside of 56%</p>\n<p>Finally, recent initial public offering<b>Coinbase</b>(NASDAQ:COIN)offers the highest perceived upside among these five fast-growing companies. Though there were only four price targets listed through this past weekend, a lofty target of $600 a share skewed the consensus up to $456 a share. This suggests Coinbase could gain 56% over the coming 12 months.</p>\n<p>There's no doubt that Coinbase has benefited from the euphoria surrounding cryptocurrencies like<b>Bitcoin</b>and&nbsp;<b>Ethereum</b>. With both rallying to new highs this year, Coinbase recorded $1.8 billion in revenue in the first quarter. For some context, that's more revenue than it had generated in the previous 24 months combined!</p>\n<p>However, unlike the other popular companies listed here,Coinbase's advantages look flimsy, at best. It runs the risk of competing crypto brokerages undercutting its fees, which could reduce its operating margins and growth rate dramatically over time.</p>\n<p>Furthermore,its business model looks to be built upon euphoria&nbsp;rather than innovation. With most of its revenue coming from Bitcoin and Ethereum trading, it's worrisome to see what happens when the price of these key assets stops rising. In a two-year stretch where Bitcoin lost 80% of its value, Coinbase saw its revenue nearly get halved.</p>\n<p>In sum, Wall Street may be bullish on Coinbase, but this Fool isn't.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Growth Stocks With 28% to 56% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Growth Stocks With 28% to 56% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-28 19:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/28/5-growth-stocks-with-28-to-56-upside-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For 13 months, Wall Street has proved virtually unstoppable. Since hitting a bear market bottom on March 23, 2020, the broad-basedS&P 500has galloped higher by 87%, through this past weekend. This ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/28/5-growth-stocks-with-28-to-56-upside-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DDOG":"Datadog","SHOP":"Shopify Inc","TDOC":"Teladoc Health Inc.","SNOW":"Snowflake","COIN":"Coinbase Global, Inc."},"source_url":"https://www.fool.com/investing/2021/04/28/5-growth-stocks-with-28-to-56-upside-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138128459","content_text":"For 13 months, Wall Street has proved virtually unstoppable. Since hitting a bear market bottom on March 23, 2020, the broad-basedS&P 500has galloped higher by 87%, through this past weekend. This handily outpaces the average bounce-back rally from a bear-market bottom and leaves the historic average annual return for the benchmark index eating dust.\nYet even at these lofty levels, Wall Street professionals see value. Based on the consensus one-year price targets of Wall Street analysts, five of the most populargrowth stocksoffer implied upside ranging from a low of 28% to as much as 56%.\n\nIMAGE SOURCE: GETTY IMAGES.\nShopify: Implied upside of 31%\nFirst up is my absolute favorite software-as-a-service (SaaS) stock,Shopify(NYSE:SHOP). Even after gaining more than 1,000% over the past 3.5 years, Wall Street believes the company's stock offers an additional 31% upside to $1,434 a share over the next year.\nShopify's operating model of providing cloud-based e-commerce solutions to (primarily) small businessescouldn't be in a better place at the moment. Although it was initially hit by the pandemic with virtually all other retail-oriented companies, it quickly became apparent that Shopify's e-commerce platform would be a logical beneficiary as businesses shifted course and pushed online. The result was a 96% increase in gross merchandise value (GMV) transacted across its platform in 2020 to $119.6 billion. Over the past six years, GMV has grown at a compound annual rate of 77.7%.\nWhat's made Shopify tick is both the discovery of the platform by new merchants and the ability to snag worthwhile deals with major retailers. The number of consumers using the platform increased by approximately 52% last year to 457 million. Meanwhile, itpartneredwith the likes ofWalmart andPinterestto streamline aspects of their online sales platforms.\nShopify isn't remotely inexpensive on a fundamental basis. But if it can continue to grow its GMV at these insane levels, investors will gladly pay a hefty premium to own Shopify stock.\n\nIMAGE SOURCE: GETTY IMAGES.\nTeladoc Health: Implied upside of 40%\nTelemedicine giantTeladoc Health(NYSE:TDOC)has been exceptionally popular over the past year, for obvious reasons I'll touch on in a moment. According to Wall Street, shares of Teladoc could ascend past $250 over the next 12 months, giving it an implied upside of 40%.\nAs you can imagine, physicians wanted to keep at-risk people and potentially infected patients out of offices and hospitals if at all possible last year. This led to Teladoc handling almost 10.6 million virtual visits in 2020, up from around 4.1 million in the previous year.\nBut understand that telehealth is agame-changing healthcare modeland not just a one-year wonder because of the pandemic. It's far more convenient for patients, allows physicians to keep closer tabs on at-risk patients, and is usually billed at a lower rate than office visits, which health insurers love. These advantages are exactly why Teladoc's sales grew by an average annual rate of 74% between 2013 and 2019.\nFurthermore, Teladoc has a new toy, so to speak: Itacquired leading applied health signals company Livongo Healthin early November. Livongo leans on artificial intelligence to send tips and nudges to patients with chronic illnesses. These nudges help patients make behavioral changes that result in their leading healthier lives. The addition of Livongo makes Teladoc a veritable no-brainer buy.\n\nIMAGE SOURCE: GETTY IMAGES.\nSnowflake: Implied upside of 28%\nAnother high-growth stock with abundant upside according to Wall Street professionals is cloud data warehousing companySnowflake(NYSE:SNOW). After recently retracing to an all-time low, analysts see Snowflake gaining up to 28% to almost $301 a share over the next 12 months.\nAs I alluded to with Shopify, we're witnessing a big push by businesses online and into the cloud, which has been a boon for most cloud infrastructure companies. Despite the worst economic downturn in decades, Snowflake grew its product revenue by 120% to $553.8 million in fiscal 2021. Although it's losing a lot of money at the moment, the services Snowflake offers should yield juicy margins as the company matures.\nArguably the most interesting thing about Snowflake is itssustainable competitive advantages. For instance, it offers a pay-as-you-go model that shuns the subscriptions that SaaS stocks often covet. By allowing its customers to pay based on their storage needs and Snowflake Compute Credits used, it's offering a highly transparent and cost-effective operating model.\nEven better, its platform islayered atop the most popular cloud infrastructure solutions, which makes the sharing of information seamless, regardless of storage provider.\nSnowflake has some very big shoes to fill with its lofty valuation, but Wall Street believes the company can get it done.\n\nIMAGE SOURCE: GETTY IMAGES.\nDatadog: Implied upside of 35%\nHave I mentioned that Wall Street has a thing forSaaS stocks? In addition to Shopify and Snowflake, analysts believe that application monitoring solutions providerDatadog(NASDAQ:DDOG)could surge to $121 a share over the next year. This implies up to 35% upside in its shares.\nKeeping with the theme, Datadog looks to benefit from businesses completely shifting their strategy in the wake of the pandemic. With employees working remotely, it's become more important than ever that businesses stay on top of key metrics, oversee critical applications, and fully understand the behavior of their customers. Datadog's cloud-based solutions do all of this for its clients.\nWhat's been most impressive about Datadog is the company's ability to attract bigger clients. While a 46% increase in customers with at least $100,000 in annual recurring revenue (ARR) is nice, the \"wow\" number is the 94% increase in the number of customers generating at least $1 million in ARR. This is a big reason the company's sales shot 66% higher in 2020 to $603.5 million.\nSimilar to Snowflake, Datadog has a lot to prove with its lofty price-to-sales ratio. However, if it can continue to grow its sales by more than 30% annually, there'sno reason Wall Street's price target isn't within reach.\n\nIMAGE SOURCE: GETTY IMAGES.\nCoinbase: Implied upside of 56%\nFinally, recent initial public offeringCoinbase(NASDAQ:COIN)offers the highest perceived upside among these five fast-growing companies. Though there were only four price targets listed through this past weekend, a lofty target of $600 a share skewed the consensus up to $456 a share. This suggests Coinbase could gain 56% over the coming 12 months.\nThere's no doubt that Coinbase has benefited from the euphoria surrounding cryptocurrencies likeBitcoinand Ethereum. With both rallying to new highs this year, Coinbase recorded $1.8 billion in revenue in the first quarter. For some context, that's more revenue than it had generated in the previous 24 months combined!\nHowever, unlike the other popular companies listed here,Coinbase's advantages look flimsy, at best. It runs the risk of competing crypto brokerages undercutting its fees, which could reduce its operating margins and growth rate dramatically over time.\nFurthermore,its business model looks to be built upon euphoria rather than innovation. With most of its revenue coming from Bitcoin and Ethereum trading, it's worrisome to see what happens when the price of these key assets stops rising. In a two-year stretch where Bitcoin lost 80% of its value, Coinbase saw its revenue nearly get halved.\nIn sum, Wall Street may be bullish on Coinbase, but this Fool isn't.","news_type":1,"symbols_score_info":{"COIN":0.9,"DDOG":0.9,"SHOP":0.9,"SNOW":0.9,"TDOC":0.9}},"isVote":1,"tweetType":1,"viewCount":966,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":386924555,"gmtCreate":1613128927477,"gmtModify":1634554417319,"author":{"id":"3575030447100890","authorId":"3575030447100890","name":"Raywjj92","avatar":"https://static.tigerbbs.com/57550c84d835f65dcf57fd3bf7c5d66b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575030447100890","authorIdStr":"3575030447100890"},"themes":[],"htmlText":"Great article","listText":"Great article","text":"Great article","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/386924555","repostId":"2110026963","repostType":4,"isVote":1,"tweetType":1,"viewCount":1312,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}